CUE
Price
$0.74
Change
-$0.05 (-6.33%)
Updated
Jun 27 closing price
Capitalization
56.38M
71 days until earnings call
PRME
Price
$2.42
Change
-$0.23 (-8.68%)
Updated
Jun 27 closing price
Capitalization
317.73M
38 days until earnings call
Interact to see
Advertisement

CUE vs PRME

Header iconCUE vs PRME Comparison
Open Charts CUE vs PRMEBanner chart's image
Cue Biopharma
Price$0.74
Change-$0.05 (-6.33%)
Volume$233.74K
Capitalization56.38M
Prime Medicine
Price$2.42
Change-$0.23 (-8.68%)
Volume$5.5M
Capitalization317.73M
CUE vs PRME Comparison Chart in %
Loading...
CUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CUE vs. PRME commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CUE is a Buy and PRME is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (CUE: $0.74 vs. PRME: $2.42)
Brand notoriety: CUE and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CUE: 129% vs. PRME: 218%
Market capitalization -- CUE: $55.83M vs. PRME: $317.73M
CUE [@Biotechnology] is valued at $55.83M. PRME’s [@Biotechnology] market capitalization is $317.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CUE’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • CUE’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, PRME is a better buy in the long-term than CUE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CUE’s TA Score shows that 4 TA indicator(s) are bullish while PRME’s TA Score has 6 bullish TA indicator(s).

  • CUE’s TA Score: 4 bullish, 5 bearish.
  • PRME’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PRME is a better buy in the short-term than CUE.

Price Growth

CUE (@Biotechnology) experienced а +5.75% price change this week, while PRME (@Biotechnology) price change was +16.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

CUE is expected to report earnings on Sep 08, 2025.

PRME is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($318M) has a higher market cap than CUE($56.4M). PRME YTD gains are higher at: -17.123 vs. CUE (-32.018). CUE has higher annual earnings (EBITDA): -37.52M vs. PRME (-200M). PRME has more cash in the bank: 144M vs. CUE (13.1M). CUE has less debt than PRME: CUE (7.13M) vs PRME (121M). CUE has higher revenues than PRME: CUE (7.99M) vs PRME (3.85M).
CUEPRMECUE / PRME
Capitalization56.4M318M18%
EBITDA-37.52M-200M19%
Gain YTD-32.018-17.123187%
P/E RatioN/AN/A-
Revenue7.99M3.85M208%
Total Cash13.1M144M9%
Total Debt7.13M121M6%
FUNDAMENTALS RATINGS
CUE vs PRME: Fundamental Ratings
CUE
PRME
OUTLOOK RATING
1..100
4235
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
6337
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (50) in the null industry is in the same range as CUE (61) in the Biotechnology industry. This means that PRME’s stock grew similarly to CUE’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as CUE (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to CUE’s over the last 12 months.

PRME's SMR Rating (98) in the null industry is in the same range as CUE (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to CUE’s over the last 12 months.

PRME's Price Growth Rating (37) in the null industry is in the same range as CUE (63) in the Biotechnology industry. This means that PRME’s stock grew similarly to CUE’s over the last 12 months.

PRME's P/E Growth Rating (100) in the null industry is in the same range as CUE (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to CUE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CUEPRME
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
85%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
74%
Advances
ODDS (%)
Bullish Trend 10 days ago
77%
Bullish Trend 10 days ago
78%
Declines
ODDS (%)
Bearish Trend 13 days ago
90%
Bearish Trend 18 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
CUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LTRE0.30N/A
N/A
Learning Tree International, Inc.
MPFRF3.60N/A
N/A
Mapfre SA
TOPCF22.38N/A
N/A
Topcon Corp.
RCRRF56.39-2.65
-4.49%
Recruit Holdings Co., Ltd.
GSVRF0.17-0.01
-5.68%
GUANAJUATO SILVER CO LTD

CUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, CUE has been loosely correlated with SGMT. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if CUE jumps, then SGMT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CUE
1D Price
Change %
CUE100%
-6.13%
SGMT - CUE
35%
Loosely correlated
-9.54%
OCS - CUE
33%
Loosely correlated
-0.67%
INAB - CUE
32%
Poorly correlated
-1.39%
HURA - CUE
31%
Poorly correlated
-0.45%
PRME - CUE
30%
Poorly correlated
-8.68%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-8.68%
CRSP - PRME
61%
Loosely correlated
N/A
RXRX - PRME
56%
Loosely correlated
-6.85%
BEAM - PRME
55%
Loosely correlated
-1.98%
CRBU - PRME
52%
Loosely correlated
-5.19%
ALLO - PRME
49%
Loosely correlated
-1.67%
More